title: GLP-1 and Amylin in the Treatment of Obesity.
abstract: For decades, extensive research has aimed to clarify the role of pancreas and gut-derived peptide hormones in the regulation of glucose homeostasis and feeding behavior. Among these are the beta-cell hormone amylin and the intestinal L cell hormone glucagon-like peptide-1 (GLP-1). They exhibit distinct and yet several similar physiological actions including suppression of food intake, postprandial glucagon secretion, and gastric emptying-altogether lowering plasma glucose and body weight. These actions have been clinically exploited by the development of amylin and GLP-1 hormone analogs now used for treatment of diabetes and obesity. This review will outline the physiology and pharmacological potential of amylin and GLP-1, respectively, and focus on innovative peptide drug development leading to drugs acting on two or more distinct receptors, such as an amylin and GLP-1 peptide hybrid, potentially producing a more effective treatment strategy to combat the rapidly increasing global obesity.
authors.affiliation: Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Kildegårdsvej 28, DK-2900, Hellerup, Denmark. tina.jorsal@gmail.com.
authors.forename: T
authors.initials: T
authors.lastname: Jorsal
authors.affiliation: Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Kildegårdsvej 28, DK-2900, Hellerup, Denmark. jr@biomed.au.dk.|Department of Biomedicine, Aarhus University, Aarhus, Denmark. jr@biomed.au.dk.
authors.forename: J
authors.initials: J
authors.lastname: Rungby
authors.affiliation: Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Kildegårdsvej 28, DK-2900, Hellerup, Denmark. filipknop@dadlnet.dk.|The NNF Center for Basic Metabolic Research and Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. filipknop@dadlnet.dk.
authors.forename: F K
authors.initials: FK
authors.lastname: Knop
authors.affiliation: Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Kildegårdsvej 28, DK-2900, Hellerup, Denmark. t.vilsboll@dadlnet.dk.
authors.forename: T
authors.initials: T
authors.lastname: Vilsbøll
mesh_terms: D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy; D004435:Eating; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D050417:Insulin-Secreting Cells / Q000187:drug effects; D058228:Islet Amyloid Polypeptide / Q000737:chemistry / Q000627:therapeutic use*; D009765:Obesity / Q000188:drug therapy*
chemical_list: D058228:Islet Amyloid Polypeptide; D052216:Glucagon-Like Peptide 1
keywords: Amylin; Dual agonist; GLP-1; Obesity treatment; Phybrid